GSK has been streamlining its global assets in recent years, with the goal of selling £1 billion worth of assets to raise cash to accelerate the public listing of its joint venture with Pfizer, and after splitting the consumer health company, GSK will focus on drugs and vaccines.

GSK has been streamlining its global assets in recent years, with the goal of selling £1 billion worth of assets to raise cash to accelerate the public listing of its joint venture with Pfizer, and after splitting the consumer health company, GSK will focus on drugs and vaccines.

In March this year, GSK cut a Canadian factory with 400 workers and transferred its factory in Mississauga and its 400 workers to Taiwan's CDMO Bora pharmatics. Under the contract, Pauli will continue to produce GSK's existing product line for at least five years.

Now, GSK has sold its production base in Poznan, Poland, along with 700 employees to French CDMO company Delpharm, and has signed a contract with Delpharm to continue to produce GSK products at the factory for more than 5 years. GSK acquired the factory in 1998 and invested $500 million in the past 20 years. By the end of 2018, the factory produced 8.7 million tablets and 1.3 million capsules per day, exporting medicines to 130 countries.

As GSK shrinks, CDMO is undergoing massive expansion, with Delpharm acquiring five factories and 1,300 workers from his financially troubled rival Famar in November 2019, giving Delpharm 17 factories around the world, including the Italian preparation factory acquired from Roche in September 2017. After acquiring Impax Laboratories' 37,000 square meters of sterile production plant and GSK Canada factory, Baorui Group has nearly 900 employees, expanding its technical capabilities and scale in the CDMO market and having the ability to support the core market in North America locally.

This article is original Kezhikang. If you want to know more industry information, please follow us.